Update: Vildagliptin for the treatment of Type 2 diabetes

Alan J. Garber, Morali D. Sharma

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Vildagliptin a selective inhibitor of dipeptidyl peptidase-4, and prevents the rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Vildagliptin has been evaluated in > 4800 patients in nine Phase III studies in the range of 24 - 52 weeks in duration: four placebo-or active-controlled monotherapy trials that enrolled drug-naive patients, four add-on studies in which vildagliptin was addedd to a stable regimen of either metformin, a sulfonylurea, a thiazolidinedione or insulin, and a study in which an initial combination, of vildagliptin plus, pioglitazone in drug-naive patients was evaluated. Across studies, vildagliptin was effective in reducing HbA1c, had a low risk of hypoglycemia and was weight-neutral and well tolerated.

Original languageEnglish (US)
Pages (from-to)105-113
Number of pages9
JournalExpert Opinion on Investigational Drugs
Issue number1
StatePublished - Jan 2008


  • DPP-4
  • Glycemic control
  • HbA
  • Type 2 diabetes
  • Vildagliptin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Update: Vildagliptin for the treatment of Type 2 diabetes'. Together they form a unique fingerprint.

Cite this